According to a survey carried out in the United States in 2023, of organizations dealing with cell and gene therapies, it was found that almost ** percent of contract development and manufacturing organizations were considering raising capital when thinking about the commercialization of these therapies. Similarly, ** percent of CGT innovators were considering raising capital in their organization, while only ** percent of healthcare providers did so.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Deloitte. (April 3, 2023). Organizations' considerations regarding commercialization of cell and gene therapies in the United States as of 2023, by organization type [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved August 02, 2026, from /statistics/1548815/issues-for-commercialization-of-cell-and-gene-therapies-in-the-us/
Deloitte. "Organizations' considerations regarding commercialization of cell and gene therapies in the United States as of 2023, by organization type." Chart. April 3, 2023. ÌÇÐÄÆƽâ°æ. Accessed August 02, 2026. /statistics/1548815/issues-for-commercialization-of-cell-and-gene-therapies-in-the-us/
Deloitte. (2023). Organizations' considerations regarding commercialization of cell and gene therapies in the United States as of 2023, by organization type. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: August 02, 2026. /statistics/1548815/issues-for-commercialization-of-cell-and-gene-therapies-in-the-us/
Deloitte. "Organizations' Considerations regarding Commercialization of Cell and Gene Therapies in The United States as of 2023, by Organization Type." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 3 Apr 2023, /statistics/1548815/issues-for-commercialization-of-cell-and-gene-therapies-in-the-us/
Deloitte, Organizations' considerations regarding commercialization of cell and gene therapies in the United States as of 2023, by organization type ÌÇÐÄÆƽâ°æ, /statistics/1548815/issues-for-commercialization-of-cell-and-gene-therapies-in-the-us/ (last visited August 02, 2026)
Organizations' considerations regarding commercialization of cell and gene therapies in the United States as of 2023, by organization type [Graph], Deloitte, April 3, 2023. [Online]. Available: /statistics/1548815/issues-for-commercialization-of-cell-and-gene-therapies-in-the-us/
